Where next with stem-cell-supported high-dose therapy for breast cancer?
- 1 March 2000
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 355 (9208) , 944-945
- https://doi.org/10.1016/s0140-6736(00)90007-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Variations in survival from breast cancer in Europe by age and country, 1978–1989European Journal Of Cancer, 1998
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of Clinical Oncology, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.Journal of Clinical Oncology, 1997
- High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.Journal of Clinical Oncology, 1997
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996
- High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.Journal of Clinical Oncology, 1995
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.Journal of Clinical Oncology, 1993